Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 2 020 JPY 0.65%
Market Cap: 3.7T JPY

Astellas Pharma Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Astellas Pharma Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Net Income (Common)
ÂĄ124.9B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Income (Common)
ÂĄ33.1B
CAGR 3-Years
-46%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Net Income (Common)
ÂĄ279.9B
CAGR 3-Years
65%
CAGR 5-Years
19%
CAGR 10-Years
-2%
Otsuka Holdings Co Ltd
TSE:4578
Net Income (Common)
ÂĄ449.1B
CAGR 3-Years
60%
CAGR 5-Years
26%
CAGR 10-Years
12%
S
Shionogi & Co Ltd
TSE:4507
Net Income (Common)
ÂĄ170.8B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
12%
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Income (Common)
ÂĄ397.2B
CAGR 3-Years
-12%
CAGR 5-Years
14%
CAGR 10-Years
21%
No Stocks Found

Astellas Pharma Inc
Glance View

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 896.78 JPY
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Net Income (Common)?
Net Income (Common)
124.9B JPY

Based on the financial report for Sep 30, 2025, Astellas Pharma Inc's Net Income (Common) amounts to 124.9B JPY.

What is Astellas Pharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%

Over the last year, the Net Income (Common) growth was 128%. The average annual Net Income (Common) growth rates for Astellas Pharma Inc have been -6% over the past three years , -2% over the past five years , and -3% over the past ten years .

Back to Top